Investments (Tables)

6 Months Ended

Dec. 31, 2022

Equity Method Investments and Joint Ventures [Abstract]

Equity investments by measurement category were as follows (in thousands):


Measurement category	December 31, 2022		June 30, 2022
Fair value	$	4,980	$	9,167
Measurement alternative	65,697		39,290
Equity method	64,099		9,918
Total	$	134,776	$	58,375

Schedule of Changes in Equity Investments

The following tables show a reconciliation of the changes in our equity investments (in thousands):


	Six Months Ended December 31, 2022
	Non-marketable securities		Marketable securities		Equity method investments		Total
Balance at the beginning of the period	$	39,290	$	9,167	$	9,918	$	58,375
Additions to investments (1)	17,132		—		57,233		74,365
Observable price adjustments on non-marketable equity securities	9,275		—		—		9,275
Unrealized losses on marketable equity securities	—		(4,187)		—		(4,187)


Loss attributable to equity method investments	—		—		(4,853)		(4,853)
Foreign currency translation adjustments	—		—		1,801		1,801
Carrying value at the end of the period	$	65,697	$	4,980	$	64,099	$	134,776

(1)Includes equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 12 herein.


	Six Months Ended December 31, 2021
	Non-marketable securities		Marketable securities		Equity method investments		Total
Balance at the beginning of the period	$	23,002	$	29,084	$	17,154	$	69,240
Net additions (reductions) to investments (2)	4,665		(3,213)		—		1,452
Observable price adjustments on non-marketable equity securities	5,367		—		—		5,367
Unrealized losses on marketable equity securities	—		(7,942)		—		(7,942)
Realized gains on marketable and non-marketable equity securities	2,355		1,637		—		3,992
Impairment of investments	(209)		—		—		(209)
Loss attributable to equity method investments	—		—		(3,300)		(3,300)
Carrying value at the end of the period	$	35,180	$	19,566	$	13,854	$	68,600

(2)Net additions (reductions) to investments includes additions from purchases, reductions due to exits of securities, or reclassifications due to our acquisition of an investee in which we held a prior equity interest.